trending Market Intelligence /marketintelligence/en/news-insights/trending/l8l0cbktrxotd1u9v2to0q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers, Compugen to study cancer medicines in collaboration

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bristol-Myers, Compugen to study cancer medicines in collaboration

Bristol-Myers Squibb Co. is collaborating with Compugen Ltd. to evaluate the Israeli company's investigational cancer medicine in an early stage clinical trial.

Compugen stocks were up 12.31% following the news to $3.65 per share as of 9:41 a.m. ET on Oct. 11, 2018.

The study will evaluate the safety and tolerability of Compugen's COM701 with Bristol-Myers' blockbuster cancer drug Opdivo to treat solid tumors. Opdivo is designed to use the body's immune system to fight cancer, while COM701 is meant to target a protein pathway in the body to enhance the immune response against the tumor.

Compugen said it will sponsor the ongoing two-part phase 1 trial, which includes the evaluation of the combination in four tumor types, including non-small cell lung, ovarian, breast and endometrial cancer.

As part of the agreement, Bristol-Myers will also make a $12 million investment in Compugen by buying 2,424,243 shares of the company at $4.95 apiece. The investment is expected to close Oct. 12.

Compugen will retain ownership and commercial rights to COM701 while Bristol-Myers will have first negotiation rights over licensing the therapy in any territory, subject to conditions.

The collaboration is also designed to address potential future combinations.

The development of COM701, an antibody, was put on hold after the U.S. Food and Drug Administration had requested more information about the medicine in April before it could approve it for use in clinical trials. However, the U.S. government's clinical trials database shows a study of the medicine is actively recruiting participants across the country.